D

Dhg Pharmaceutical Joint-Stock Co
VN:DHG

Watchlist Manager
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
Watchlist
Price: 105 100 VND -0.66% Market Closed
Market Cap: 13.7T VND
Have any thoughts about
Dhg Pharmaceutical Joint-Stock Co?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

13.1
Current
11.5
Median
13.8
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
13.1
=
Enterprise Value
12.1T VND
/
EBITDA
919.5B VND
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
VN
D
Dhg Pharmaceutical Joint-Stock Co
VN:DHG
Average EV/EBITDA: 414.9
13.1
2%
6.6
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 459 134.4 N/A N/A
US
Eli Lilly and Co
NYSE:LLY
47.8
43%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
20.6
22%
0.9
US
Johnson & Johnson
NYSE:JNJ
11.5
4%
2.9
US
Merck & Co Inc
NYSE:MRK
10.5
63%
0.2
CH
Roche Holding AG
SIX:ROG
9.9
7%
1.4
UK
AstraZeneca PLC
LSE:AZN
169.4
18%
9.4
CH
Novartis AG
SIX:NOVN
9.5
3%
3.2
US
Pfizer Inc
NYSE:PFE
10.6
9%
1.2

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
12
2-Years Forward
EV/EBITDA
11.2
3-Years Forward
EV/EBITDA
10.4

See Also

Discover More